It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...

A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.

Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...

The FTSE 100 headed lower as trading got underway on Friday, in line with a drop for heavyweights AstraZeneca PLC (LON: AZN) ...

Freddie Farrow died after the ‘very large mirror’ fell on to him in the Fenwick department store in Colchester on July 27 ...